Retinoblastoma: identifying the diagnostic signs for early treatment. by Thompson, Simon et al.
Retinoblastoma: Identifying the Diagnostic Signs for Early Treatment
Simon B N Thompson1,2*, Holly Chinnery1, Siamak Noroozi3, Bryce Dyer3 and Ken Barratt4
1Psychology Research Centre, Faculty of Science & Technology, Bournemouth University, UK
2International Scientific Council for Research, Université Paris X Ouest Nanterre La Défense, France
3Design Simulation Research Centre, Faculty of Science & Technology, Bournemouth University, UK
4National Artificial Eye Service, National Health Service, Blackpool, UK
*Corresponding author: Simon B N Thompson, Associate Professor of Clinical Psychology & Neuropsychology, Psychology Research Centre, Faculty of Science &
Technology, Bournemouth University, Poole, BH12 5BB, UK, Tel: 01202 961558; E-mail: simont@bournemouth.ac.uk
Rec date: Feb 27, 2015; Acc date: Apr 22 2015; Pub date: Apr 28, 2015
Copyright: © 2015 Thompson SBN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Retinoblastoma is a rare but significant cause of childhood eye cancer world-wide. The prognosis depends upon
early diagnosis and treatment but also upon accurate classification of the tumours. Unilateral incidence is normally
non-hereditary compared with bilateral incidence where secondary tumours are more common. Survivorship is much
better for unilateral compared with bilateral and trilateral retinoblastoma. Early signs are important to detect and
photography can assist in identifying no return of “red-eye” during flash photography and yellow appearance of the
tumour. Treatment options are discussed together with new psycho-oncology approaches that address potential
trauma in the survivor as well as in the family of the survivor.
Keywords: Childhood cancer; Diagnosis; Eye cancer; Prognosis;
Rehabilitation; Retinoblastoma; Treatment
Introduction
The human eye is a complex organ that allows immense detail to be
assimilated and, with both eyes, enables judgement of depth via
stereoscopic vision. Sometimes, poor vision is overlooked, especially in
children, when the ability to express difficulty is limited, or when the
effects of poor vision are subtle. In particular, Retinoblastoma (Rb) is a
rare type of eye cancer but the most common intraocular malignancy
of early childhood [1-3], forming 3 per cent of all childhood cancers
[4]. It is an aggressive disease that evolves as a tumour of the retina,
the thin layer of cells on the inside at the back of the eye [5].
Although almost exclusively a cancer of childhood, it has been
detected in the foetus and can also occur in older children [6]. Rb
presents from birth to 5 years of age, typically being diagnosed in
children before the age of 3 years of age [7, 8]. In terms of prevalence,
it is equal in regard to age, sex, and right or left eye [9].
In the UK, it affects between 40 - 50 children every year [10] and
occurs because of errors or mutations to a gene we all possess called
the RB1 gene [1]. Reports of small sample cohorts from the
Netherlands show that relative risks following in-vitro fertilisation are
significantly raised, though the possible association in population-
based studies is yet to be established [11].
Data for the period of 2006-2010 show a five-year survival rate of
100 per cent, in the UK [10]. Survival rate in developed countries
averages at 95 per cent compared to 50 per cent worldwide [8, 11].
Delay in presentation, diagnosis and access to resources are the most
common explanations for this difference [12].
Genetic inheritance
We inherit two copies of the RB1 gene, one from each parent. If
both copies of this gene are damaged in a single cell, followed by a
chance mutation in the child’s retinal cells, then one of the important
“brakes” or “stops” of cell growth and cell division is lost giving rise to
tumours in the retina. During the early stages of eye development,
retinoblasts (cells) divide into new cells and fill the retina. At a certain
point the cells stop dividing and develop into mature retina cells that
detect light. In rare cases retinoblasts continue to divide and grow out
of control forming Rb [14].The RB1 gene is located on chromosome
13, position 14.2 and is a tumour suppressor gene [3]. Each cell
normally has two RB1 genes. As long as a retinal cell has one working
RB1 gene, it will not form Rb. However, when both Rb1 genes are
mutated or lost, gene changes occur which may cause cells to become
cancerous.
Genetically, there are four possibilities: firstly, if the mutated gene is
present in the parent with the disease or if the parent is a carrier of the
disease, and if the child’s retina mutates, then tumours typically occur
bilaterally [15] and with a high risk to the brothers and sisters and
future children also having the bilateral disease. There are treatment
options in these cases but often the child loses substantial sight in one
or both eyes and if the tumour is aggressive and large then the eye is
also lost and necessitates a surgical implant.
The second genetic scenario is when the RB1 gene has not mutated
within the parent but instead it mutates in either the egg or sperm.
This gives rise to Rb if the child’s retinal cells also mutate. Thirdly,
mutation of the RB1 gene may occur during early embryonic
development before the cells are defined and if mutation occurs in the
retina of the unborn child then Rb can occur unilaterally or bilaterally
with lower risk to brothers and sisters and to future children.
Lastly, if the gene mutates in the retina of the healthy child, then Rb
often occurs unilaterally with a low risk for brothers and sisters and
future children. There is a risk in all scenarios of secondary cancers
occurring later in life to soft tissue areas and to bone. There has been a
step away from classifying using “genetic” and “non-genetic”
terminology since theoretically, all scenarios are “genetic”, i.e. involve
mutation of the RB1 gene.
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The genetic possibilities are “heritable” versus “non-heritable”
though “mosaic” has been used when the picture may be less definitive
and if some but not all cells carry the mutated gene but only one eye
has appeared with Rb tumours.
It is estimated that 40 per cent of children with Rb have a germ-line
mutation in one RB1 gene, thus all the cells in the body have a
defective RB1 gene [6,16]. In 25 per cent of these cases, the child has
inherited it from one of their parents. The remaining 75 per cent is the
result of a mutation developed after conception while in the womb
[15]. Hereditary Rb is diagnosed on average at one year of age and the
child is more likely to have multifocal and bilateral disease [15].
Having the genetic form of the disease also increases the child’s risk of
developing secondary primary cancers.
The most common secondary primary tumours are osteosarcomas,
brain tumours and soft-tissue sarcoma [16]. Fontela et al. [17]
reported that patients with bilateral disease are at a 5 per cent chance
of developing another cancer during the first 10 years of follow-up, 18
per cent within the first 20 years and 26 per cent within the first 30
years. This makes secondary primary tumours the greatest cause of
death for patients with Rb [6].
If a child has the hereditary form of Rb, yet they do not have an
affected parent (as the mutation happened in the womb), the chance
that the parents will conceive another child with Rb is less than 5 per
cent. However, the patient with hereditary Rb has a 50 per cent chance
of passing the abnormal gene onto their offspring [15] which is why
this form of Rb is called hereditary.
The remaining 60 per cent of children with Rb do not have the Rb1
gene mutation in all cells of the body. Instead, the Rb1 mutation
occurs early in life in a single retinal cell by chance, sometime after
conception [4]. As of yet, it is not known how or why this occurs [18].
Patients with non-hereditary Rb have unilateral, unifocal disease [8]
with the average age at diagnosis being two years of age and the disease
is not passed to the patient’s offspring.
The disparity in age of onset and tumour number and location
between the hereditary and non-hereditary form of Rb supports
Knudson et al. [15] ‘two hit’ hypothesis [3]. If a patient with unilateral
or bilateral Rb has relatives with the disease, it can be assumed that the
patient has the inherited form of Rb. However, it cannot be assumed
that a patient without a family history of the disease has the non-
hereditary form. In other words, whilst all bilateral cases are
hereditary, not all unilateral cases are non-hereditary. 10 per cent of
patients with unilateral disease have underlying germline mutation
and are at risk of developing the disease in the uninvolved eye [4]. It is
therefore necessary to have all patients with Rb genetically tested to
determine whether the Rb is (non) hereditary [7].
The current techniques that are used can detect 90 per cent of
mutations in patients with bilateral Rb and 85 per cent in patients with
unilateral Rb and in contrast, 87 per cent of unilateral Rb is caused by
post-zygotic mutation occurring at the early stages of embryo
development that can lead to mosaicism [19].
Trilateral Rb occurs in 5 per cent to 15 per cent of patients with
heritable Rb: usually bilateral but can also be unilateral [20]. Trilateral
Rb results from the development of an independent brain tumour that
forms in the pineal gland. Trilateral Rb is relatively uncommon, does
not result from the spread of intraocular Rb and is usually fatal. The
condition is usually diagnosed 2 years following diagnosis of Rb and
has a median survival time from diagnosis of the disease of 9 months.
Given the poor prognosis and the short interval between diagnosis
of Rb and the occurrence of trilateral disease, imaging tests are
recommend every 6 months for five years for those with the hereditary
disease or unilateral disease and a positive family history [20].
Diagnosis
Early diagnosis is essential if the tumours are to be detected and
treated and if the spread of tumour is to be stopped. Often parents
may see an unusual colour in the eye or eyes of their children when
photographed such as a yellow colouring (a little similar to a cod liver
oil capsule) or a white colour (Figure 1) [13] rather than the natural
red pigment of the retina [1]. Flash photography using the installed
camera of a modern mobile phone (commonly, backside-illuminated 5
megapixel, or greater, rear-facing camera, with 3.85 mm f/2.8 lens) is
ideal for detecting the normal “red eye” that should be reflected from
the retina. Author 1, suggests that, anecdotally, close-up flash
photography in this manner is helpful and often re-assuring as initial
screening but parents are advised to seek professional confirmation if
there is any doubt about these signs especially since early detection of
Rb is of paramount importance.
Figure 1: Yellow colour depicting typical eye tumour compared
with normal red of retina [13]
Associated signs such as a strabismus (squint) or head-turning in
compensation for poor sight, may also be noticed in a child with Rb.
Curiously, some children who have lost one of their senses or who
have lost one of their sense organs early in life may compensate for the
loss; and reports indicate that there is often normal cognitive
development [21]. Compensation can occur by having “super-
functioning” in the remaining functional eye. It would seem that
losing the sight (and often the eye) before the age of one years’ old may
result in functioning of the remaining healthy eye to be better than
average in terms of sight and visual functioning acuity. It has also been
seen in those who have lost other senses such as hearing or who have
lost sight completely and have developed acute hearing, touch, or taste
senses instead [21]. It is as if additional meaning is gained in the
remaining sensory mechanisms. As the famous philosopher and
writer, Thomas Carlisle wrote, “… indeed it is well said. In every
object there is inexhaustible meaning. The eye sees in it what the eye
brings means of seeing.” [22].
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The prognostic outcome of life and vision in patients with Rb has
significantly improved in recent years. Factors such as improved
methods for diagnosis and treatment, and age and stage of tumour(s)
as well as type of Rb, have a contributing role. Patients diagnosed
before the age of two are thought to have a higher survival rate than
those diagnosed at two years or older. Reasons for this include
advanced presentation and an increased risk of extra-ocular extension
and metastasis in those who are diagnosed at a later age [23].
Consequently, more intensive treatment is required which may
adversely affect vision and survival of the patient.
Patients with intraocular Rb have a five-year survival rate of 98 per
cent compared to 10 per cent in patients with extra-ocular Rb.
Furthermore, patients with the hereditary from of Rb have a higher
risk of developing secondary primary cancers and are susceptible to
the development of trilateral Rb [20]. Those with trilateral Rb have an
average survival rate of eight months when treated compared to one
month in those untreated.
Clinical manifestations of Rb vary dependent on the stage of the
disease [4,9]. The most common presenting sign at 60 per cent is
leukocoria [6]. When a bright light is shone into an eye, blood vessels
will reflect a red colour back. In those with Rb the pupil will appear
white or yellow. This is also known as ‘Cat’s eye’ and is often
noticeable when a photograph is taken using the flash [8]. As a late
manifestation of Rb, the tumours are likely to be large. However
prognosis remains high at 88 per cent of the five-year survival rate [6].
The second most common sign at 20 per cent is strabismus. As an
early sign, prognosis and eye salvage is high. Strabismus
(misalignment of the eye) results from a loss of central vision in one or
both eyes [7]. It involves a lack of coordination between the
extraocular muscles preventing the gaze of each eye at the same point.
Thus, one eye may look straight ahead, upward, downward or
outward. Other presenting symptoms include reddish pupil, larger
than normal pupil, poor or decreased vision, wandering eyes
(nystagmus) and parental history of Rb [23].
If Rb is suspected, a red reflux test needs to be conducted [9]. This
test is used to view both reflexes at the same time in order to
determine if the patient has normal ocular alignment. The test is
conducted in a dimly lit or dark room using an ophthalmoscope at 50
cm away from the child. This allows simultaneous illumination of both
eyes making it easier to compare the reflex. Pupillary dilation has been
found to be helpful when performing this test. To be considered
normal, a red reflux will be systematic and shown in both eyes. Dark
spots in the red reflux, a diminished reflux and the presence of a white
reflux indicate an abnormality [1]. Thus, an urgent referral to an
ophthalmologist for further evaluation is required [24,25]. It is advised
that children with a positive family history of Rb are screened soon
after birth. This needs to be repeated every four to six weeks up to the
age of one year and then every two to three months until three years of
age [25].
Once Rb has been diagnosed, imaging tests are conducted to find
out if the cancer has spread within or beyond the eye. This process is
known as staging. Staging not only depicts how far the cancer has
spread, it also provides prognosis of survival, outlook for saving vision,
size and location of the tumour(s) and likelihood that certain
treatments will be effective [3]. Imaging tests used in the detection and
diagnosis of Rb are ultrasound, Magnetic Resonance Imaging and
Computerised Tomography scan [26].
Diagnostic tools
An ultrasound (echography) examination helps determine the
thickness or height of the tumour [26]. Whereas most children with
Rb will have one Magnetic Resonance Imaging scan [8] that provides
detailed images of the eye and surrounding areas such as the spinal
cord and brain, those with bilateral Rb may have scans for several
years after treatment to ensure no further spread. The procedure in
children often requires a general anaesthetic to achieve complete
stillness in the patient.
Computerised Tomography scan, often with contrast medium dye,
is helpful for detailed cross-sectional images [7], particularly to
determine the size of the Rb tumour and its spread within the eye and
to nearby areas. Despite the effects of radiation, calcification is
detected better using this test and is particularly helpful when the
diagnosis of Rb is not clear.
In cases where there is a strong reason to think that Rb has spread
to the skull or other bones, a bone scan is undertaken. However, it is
important to be aware that the areas may be a result of other bone
changes [18]. Other types of tests that are carried out when there are
additional symptoms (weight loss, vomiting), or abnormal findings
associated with the diagnosis of Rb include blood tests (particularly,
for liver and kidney functioning and changes in chromosome 13),
lumbar puncture and bone marrow aspiration and biopsy.
Differential Diagnosis
Due to a number of ocular disorders in children clinically
resembling Rb, it is important that the diagnosis of Rb is fully
confirmed prior to the start of treatment. Shields and colleagues [27]
found that 42 per cent of patients who were referred with possible Rb
had lesions that simulated Rb. In this study a total of 23 different
conditions were accounted for the pseudo-retinoblastoma including
persistent hyperplastic vitreous (blurred vision due to scarred
vitreous), Coats disease (abnormal development of blood vessels
behind the retina) and presumed ocular toxocariasis (rare infection
caused by roundworms). Patients with these diseases often present
with leukocoria - the most common presentation in Rb. Other less
common conditions that may mimic Rb are congenital cataract,
retinopathy of prematurity, Norrie disease and familial exudative
vitreoretinopathy [28]. A careful clinical examination using the red
reflux test as described above is usually sufficient to determine the
correct diagnosis.
Staging
Rb is staged on the results of eye exams, imaging tests and in rare
cases, biopsies. The stage of Rb determines best treatment option and
can help predict a patient’s prognosis. Rb is staged on the basis of
whether it is intraocular, extra-ocular or recurrent.
Intraocular Rb is the earliest stage of the disease where the cancer is
still within the eye. It may be confined to the retina or extend to other
structures such as the optic disk, choroid or anterior chamber,
however, does not extend beyond the eye. If left untreated for 12
months, metastasis is likely to occur and can become fatal within a few
years [9].
Extra-ocular Rb is an advanced stage of disease where the cancer
has spread outside of the eye. In these cases cells break away from the
main tumour on the retina and float through the vitreous to reach
other parts of the eye [18]. The cancer can spread either to the tissues
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around the eye (orbital Rb), the central nervous system (CNS) or to
the bone marrow or lymph nodes (metastatic Rb).
In the majority of cases, extra-ocular Rb occurs in developing
countries due to late detection, limited access to resources and thus
delayed diagnosis [28]. Recurrent Rb is where the tumour has recurred
or progressed following initial treatment. The recurrent tumour may
be confined to the eye, tissues surrounding the eye or other parts of the
body.
In the UK, Rb is primarily detected and diagnosed before it has
spread outside of the eye. Therefore, staging systems that apply only to
intraocular Rb are used most often in this country. There are two main
staging systems for intraocular Rb: the Reese-Ellsworth staging system,
and the International Classification for Intraocular Rb. In the 1960s
the Reese-Ellsworth classification was created based on intraocular
tumour staging and globe savage after external beam radiotherapy
(EBRT) [6]. The system divides eyes into 5 groups (I to V) and 10
subgroups (‘a’ and ‘b’ for each group) according to location, focus and
the size of the tumours. Group I have the lowest risk of treatment
failure and group V has the highest risk of enucleation. Tumour
control for group I – III was reported to be 78 per cent compared to 20
per cent in group III-V [29].
During this era EBRT was the treatment modality of choice,
however it had little success with multifocal and large tumours due to
technical difficulty [29]. Consequently, these tumours were presumed
more aggressive and were given a higher ranking in the classification
system, implying a worse ocular prognosis [26].
With radiation being linked to disfigurement and increasing the
risk of developing secondary cancers, particularly in those with
hereditary Rb, chemo-reduction combined with focal treatments
became the primary treatment modality [30]. This shift in treatment
modality found that multifocal and large tumours do not have a worse
prognosis than small, solitary macular tumours.
What emerged as the difficulty in treating Rb was the management
of vitreous and sub-retinal seeds. By not addressing seeding, the Reese-
Ellsworth classification was found to be a poor predictor of chemo-
reduction success [31]. This led to the International Classification of
Rb (ICRB) being developed in 2003, which is predominately based on
the extent of sub-retinal and vitreous seeding with minor
consideration of tumour size and location [29].
The International Classification of Rb (2003) is a staging system
that divides intraocular Rb into 5 groups labelled A to E (Table 1). It is
based on the natural history of Rb (early stage, group A to late stage
group E) and on the likelihood of saving the eye following primary
treatment of chemotherapy and adjuvant focal therapy [29]. Each eye
is staged independently and the tumour with the higher grade is used
to classify the eye.
GROUP TUMOUR
A Confined to retina; away from visual structures
such as optic disk; < 3mm across.
B Close to visual structures; > 3mm across.
C Well-defined; small seeding.
D Large; Widespread seeding.
E Extensive; destruction of eye.
Table 1: The International Classification of Retinoblastoma
In group A and B the tumour remains confined to the retina. Group
A tumours are less than 3 mm across and away from visual structures
such as the optic disk whereas group B tumours are more than 3 mm
and close to the visual structures. In group C and D, the tumours have
spread into the sub-retinal and vitreous cavity. Group C indicates well
defined tumours with small seeding compared to group D where there
is widespread seeding and large tumours. Group E refers to extensive
tumours that have destroyed the eye. Group A has the lowest risk of
treatment failure whereas group E eyes are rarely salvageable,
requiring additional EBRT or enucleation [32]. The chance of
retaining useful vision decreases from group A to E [29].
Several classification systems have been developed for extra-ocular
Rb, and some for both intraocular and extra-ocular Rb. Extra-ocular
staging applies to cancer that has spread outside of the eye and takes
into account the degree of local extension, intracranial metastasis and
haematological metastasis. The International Rb Staging System
(IRSS) encompasses both intraocular and extra-ocular Rb (Table 2).
The IRSS is based on the extent of the disease [8]. The staging system
is split into 5 sections ranging from stage 0 to stage IV. Stage 0 refers to
intraocular cancer, thus patients with this stage of disease should be
classified based on the International Classification System.
STAGE STATUS
0 Intraoccular – refer to International Classification of Retinoblastoma.
I Enucleation; some microscopic spread to optic nerve.
II Spread to optic nerve and sclera.
IIIa Spread to eye socket tissues.
IIIb Spread to lymph nodes near to ear and/or neck.
IVa Spread to blood; one or more tumours.
IVb Spread to brain and/or spinal cord.
Table 2: International Retinoblastoma Staging System
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Stage I refers to eyes that have been enucleated and there is some
microscopic spread to the optic nerve. Stage II refers to tumour spread
to the sclera as well as the optic nerve. Stage III is divided into two sub-
stages: llla where the cancer has spread to tissues around the eye socket
and lllb where the cancer has spread to lymph nodes near the ear or in
the neck. Stage IV is also divided into two sub-stages: IVa where the
cancer has spread to the blood where there are one or more tumours.
IVb refers to cancer that has spread to the brain or spinal cord.
The TMN classification is particularly useful in describing the
extent of Rb. It takes into account the size of the primary tumour and
how far it has grown within and outside of the eye; whether or not the
cancer has reached the lymph nodes and whether it has metastasised to
other sites such as the bone marrow and brain [18].
Recurrent Rb
Recurrent Rb is cancer that has returned or continues to grow after
treatment. The cancer may come back in the same place (local
recurrence), nearby (regional recurrence), or in another place, (distant
recurrence). Further testing is undertaken in order to restage the
cancer. The cancer is re-staged depending on whether it is intraocular
or extra-ocular. Intraocular and extra-ocular recurrences have very
different prognoses and are treated in distinctly different ways.
Treatment Options
The goals of treatment for a patient with Rb are to save the patient’s
life, to save at least one eye and to prevent vision loss [18]. The
management of Rb needs a multidisciplinary team approach including
an oculist, paediatric oncologist, geneticist and an ophthalmic
oncologist [32].
Treatment of Rb is highly individualised and is dependent on
whether the cancer is intraocular or extra-ocular, unilateral or bilateral
and unifocal or multifocal. Additional features that affect treatment
choice include the age of the child, family and societal perception,
overall prognosis, cost effectiveness of treatment and the size, location
and number of tumours [32]. Treatment of Rb in the UK is primarily
based on intraocular disease due to its high percentage at diagnosis.
There are several methods to manage intraocular Rb including focal
therapy (photocoagulation, thermotherapy, cryotherapy and
brachytherapy), local therapy (external beam radiation and
enucleation), and systemic therapy (chemotherapy). While primary
focal therapy treats small tumours, local and systemic therapy treats
advanced tumours [32]. Combinations of treatments may be required
to achieve tumour control [30].
Intraoccular Rb
Focal therapy: Focal therapy refers to a group of treatments that are
applied directly to the eye. Focal therapy is performed under general
anaesthetic and is repeated numerous times until all remaining signs
of active tumour has disappeared [33]. A noticeable side effect of focal
therapy is scarring of the retina thus affecting vision.
There are four main types of focal therapy used to treat Rb:
photocoagulation, thermotherapy, cryotherapy and brachytherapy.
Focal therapy is generally used to treat small to medium tumours that
fall into group A-C on the International Classification for Intraocular
Retinoblastoma and groups I to IV on the Reese Ellsworth
Classification for Intraocular Retinoblastoma.
Photocoagulation therapy: Photocoagulation, also known as laser
therapy, is used for small tumours, measuring less than 3.5 mm in
thickness, residual tumour after chemotherapy and recurrence after
chemotherapy [3]. Photocoagulation uses heat in the form of a laser to
physically destroy tumour cells. The laser is directed to the affected
areas of the retina through the pupil. Pharmaceutical drops are used to
dilate the pupil. The heat of the laser cauterizes the blood vessels that
surround and supply the tumours [9].
On average, photocoagulation is delivered 2 or 3 times with a
month between treatments [11]. Photocoagulation is a painless
procedure although the eye may be red following treatment. In rare
cases photocoagulation can damage the retina, which can lead to blind
spots or temporary retinal detachment.
Thermotherapy: Thermotherapy is recommended for small
tumours, measuring 4 mm in diameter and 2 mm in thickness, close to
the fovea or optic nerve, where other therapies might create greater
visual loss [9]. Thermotherapy involves the use of heat to help shrink
tumour cells. The heat often used in treating Rb is infrared rays and is
directed either on the whole eye or localised to the tumour area [11].
The tumour is heated at a temperature between 40 and 60 degree
Celsius until it turns a subtle grey, in order not to damage the retinal
vessels [30]. Complete tumour regression can be achieved in 85 per
cent of tumours using 3 to 4 sessions. Common complications include
retinal detachment, clouding of the lens, shrinking off the iris and
damage to the retina [30].
Cryotherapy: Cryotherapy is primarily used to treat small tumours,
measuring up to 4 mm in diameter and 2 mm in thickness, located on
the front part of the retina [11]. Cryotherapy uses liquid nitrogen to
destroy the Rb cells by freezing them [9]. A small metal probe is placed
on the outer surface of the eyeball next to the tumour, which is frozen
and thawed several times.
The thawing process kills the tumour cells as ice crystals pierce the
tumour membranes destroying the cells. Cryotherapy is delivered 2 or
3 times with a month between treatments [18]. Cryotherapy may cause
the eye and eyelid to swell for a few days and can damage the retina
leading to blind spots and temporary retinal detachment.
Brachytherapy: Brachytherapy, also known as plaque radiotherapy,
is used for small to medium sized tumours less than 15 mm in
diameter and 10 mm in thickness that are situated away from the optic
nerve and centre of vision. Brachytherapy can also be used as
secondary measures after prior failed treatment such as cryotherapy or
in the case of recurrence [6,9].
Brachytherapy involves the application of radioactive material to
the outer surface of the eye (sclera) at the base of the tumour.
Commonly used radioactive material includes Ruthenium 106 and
Iodine 125 [33]. The radioactive material is put into a small carrier
known as a plaque, which delivers a low dose of radiation directly to
the tumour.
The plaque is surgically attached to the outer part of the eyeball,
directly over the tumour. The plaque is left in place for between two
and five days before being surgically removed. Brachytherapy has a 90
per cent tumour control rate but can lead to the development of a
cataract. However, this can be corrected with surgery once the Rb is
under control [33].
Local therapy: Local therapy or external beam radiation therapy was
the preferred form of Rb management in the 1990’s. However, the
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long-term complications such as damage to nearby body tissue, the
increased risk of developing secondary cancers, particularly in those
patients with hereditary Rb, stunting of the orbital growth, dry eye,
and cataract, led to the development of newer chemotherapy protocols
[33].
External beam radiation therapy is most often used in advanced
cases of Rb such as advanced bilateral cases or recurrence [3]. It is also
indicated in eyes that contain one or more tumours that involve the
optic disc, a tumour that is larger than 16 mm in diameter, where there
is sub-retinal seeding, and for eyes where primary chemotherapy and
local therapy has failed. It may also be used to treat the eye socket after
enucleation if there is extension behind the area [25].
External beam radiation therapy uses an invisible form of high
energy (like x-rays) to kill cancer cells or keep them from growing or
dividing [28]. A linear accelerator machine directs radiation to the
precise area of the eye needing treatment. However, if the cancer is
extensive, radiation treatment of the entire eye may be necessary. The
treatment is given in doses measured in unites called centigrays (cGy).
Ray and Gombos [3] reported a dosage of 45-50Gy given in 1.5 - 2
Gy per fraction. Radiation is usually given 5 days a week for several
weeks with the delivery only taking a few minutes.
Enucleation: As a result of earlier tumour detection as well as
improved use of more conservative eye-sparing treatments such as
focal therapy, there has been a significant decrease in the use of
enucleation in patients with Rb over the last 40 years [3]. However,
enucleation remains a frequent treatment for Rb and is indicated for
all unilateral tumours that fill over half the eye, where there is
extensive seeding, retinal detachment, high risk of metastasis and
tumour invasion into the optic nerve [3].
In patients with bilateral Rb, the eye with the more advanced
tumour will be enucleated and the less affected eye managed by other
therapies [7]. If neither eye has useful vision because of damage
already caused by the cancer, enucleation of both eyes will be
undertaken to make sure that all the cancer is gone. Thus, enucleation
primarily occurs in groups D-E of the International Classification for
Intraocular Rb and group V of the Reese-Ellsworth Classification of
Intraocular Rb.
Enucleation is the surgical removal of the eyeball, leaving the 6
extra-ocular muscles and the contents of the eye socket intact [25].
Enucleation is performed under general anaesthesia with the
procedure taking 60-90 minutes. Immediately after the eyeball has
been removed, an orbital implant is inserted into the socket. The eye
muscles are attached to the implant to improve motility and the
implant is covered externally with the conjunctiva (pink surface tissue
that lines the eyelid) and sutured in place [25].
The patient is then fitted with a conformer shell made of clear
acrylic resin offering a smooth curved surface over which the eyelids
blink without rubbing the suture line. The shell maintains the shape of
the eye socket and helps stop infection. It has a small hole to allow
drainage and is marked with a letter to indicate its size. A pressure pad
is worn over the empty socket for 12 to 48 hours after the operation to
help reduce tissue swelling in the socket. Side effects of enucleation
include bruising, ptosis (droopy eyelid), haemorrhage, infection,
scarring of the socket and extrusion of the implant [23].
Chemotherapy: Systemic therapy or chemotherapy is an effective
treatment for large tumours or tumours that are located near the optic
nerve or centre of vision [25]. Chemotherapy is the use of anti-cancer
drugs to destroy cancer cells by stopping them from growing or
multiplying [25]. The chemotherapy drugs most commonly used for
treating Rb are etoposide, carboplatin and vincristine [5]. Often two or
more drugs are given at the same time depending on the extent of the
tumour [25].
Chemotherapy can be given in several different ways, but is most
often given intravenously (IV) through a vein or orally. This is known
as systemic chemotherapy [25]. Systemic chemotherapy is where the
drugs travel through the bloodstream to eradicate the cancer rather
than being applied directly to the cancer [18]. When given
intravenously, the chemotherapy drugs travel through a device called a
port-o-cath. The port-o-cath is surgically inserted under the skin of
the patient’s chest and is attached to large blood vessels.
The chemotherapy drugs travel through the bloodstream to enter
the blood supply of the tumour where they begin to destroy it. By
being directly inserted into the bloodstream reduces the risk of harm
to the surrounding tissues. Systemic chemotherapy is given in cycles of
treatment followed by a rest period. Each cycle lasts a few weeks with
the total length often being several months; though this is dependent
on how well the tumour responds [18].
These methods can expose the entire body to significant doses of
chemotherapy, thus can result in unwanted and sometimes long-
lasting side effects such as hair loss, mouth sores, damage to the heart,
kidneys and lungs, nausea and vomiting, fatigue and increased chance
of infections [34]. Intra-arterial chemotherapy is a new treatment for
advanced Rb [11]. The chemotherapy drug (melphalan and/or
topotecan) is delivered through the blood vessels [30].
A thin catheter is inserted into a large artery on the inner thigh and
threaded through blood vessel into the ophthalmic artery. The
chemotherapy drug is then infused into the artery. This method is
designed to minimise the drug’s exposure to the rest of the body and
to reduce side effects often seen in systemic chemotherapy [18]. The
average number of treatment sessions is three for each eye with each
session being delivered at four-week intervals. Due to its recent
development, the long-term effects of this treatment is yet unknown.
However, early reports indicate up to 100 per cent globe salvage for
group C and D of the International Classification of Intraocular Rb
[29]. Typically chemotherapy is used in addition to other therapies in
order to either shrink a tumour before other therapies, known as neo-
adjuvant therapy or chemo-reduction, to destroy cancer cells that
remain after therapy, for example post-enucleation called adjuvant
chemotherapy or to help destroy cancer if it spreads or recurs [25].
Chemo-reduction: Chemo-reduction has become an important
therapeutic tool in treating Rb [30]. Chemo-reduction is a method of
using intravenous chemotherapy to reduce the size of the tumours so
that residual tumours can be eradicated with focal treatment methods.
This approach results in 85 per cent globe salvage of eyes classified as
Reese-Ellsworth groups I to IV, compared to 47 per cent in group V
[31]. Chemo-reduction coupled with focal therapies can minimise the
need for enucleation or external beam radiation therapy.
Chemo-reduction is used in nearly all children with bilateral Rb and
about 25 per cent of children with unilateral Rb [30]. It is most
successful for tumours without sub-retinal fluid or vitreous seeding.
Extra-ocular Rib: Few patients in developed countries present with
extra-ocular Rb. Extra-ocular disease may be localised to the soft
tissues surrounding the eye or to the optic nerve, brain, or central
nervous system.
Citation: Thompson SBN,Chinnery H, Noroozi S, Dyer B, Barratt K (2015) Retinoblastoma: Identifying the Diagnostic Signs for Early Treatment.
Int J Neurorehabilitation 2: 1000160. doi:10.4172/2376-0281.10001360
Page 6 of 11
Int J Neurorehabilitation
ISSN:2376-0281 Open Access Volume 2 • Issue 2 • 160
The standard treatment options for when the cancer has spread
within the eye, known as orbital and loco-regional metastasis, is
chemotherapy and radiation therapy; with the cure rate standing at 60
to 85 per cent [30]. Orbital Rb occurs as a result of progression of the
tumour through the sclera and occurs in 60 to 70 per cent of patients
with extra-ocular disease.
Patients with stage I to III extra-ocular Rb have had an eye removed
yet there is some microscopic spread to the optic nerve, lymph nodes
or bone cavity. Patients with spread to these areas require adjuvant
chemotherapy and possibly radiation therapy after enucleation [30].
Adjuvant chemotherapy destroys microscopic cells in order to prevent
a possible cancer recurrence.
Stage IV encompasses extra-ocular spread to distant areas of the
body outside of the eye such as the central nervous system. This stage
of extra-ocular Rb is treated with high dose chemotherapy and/or
radiation therapy to destroy as many cancer cells as possible, before
being given a stem cell transplant. A stem cell transplant is where
hematopoietic stem cells are given to a patient to replace bone marrow
that contains cancer. These cells grow into healthy blood cells to
replace the ones the patient lost [32].
Recurrent Rb: Recurrent Rb is cancer that has returned after it has
been treated. The cancer may recur in the eye, (intraocular), in tissues
around the eye, or in other places in the body (extra-ocular).
Furthermore, the cancer may come back in the same place (called a
local recurrence), nearby (regional recurrence), or in another place
(distant recurrence).
When this occurs, tests will be undertaken to determine location,
size and how aggressive the new tumour is. Treatment for recurrent
intraocular Rb may include enucleation, external beam radiation
therapy, systemic chemotherapy and/or focal therapy [28]. Treatment
failure necessitates additional external beam radiation in 10 per cent of
patients and enucleation in 15 per cent of patients at five-year follow-
up. Recurrent extra-ocular Rb can be treated with systemic
chemotherapy, radiation therapy and stem cell transplant. Long term
monitoring will detect possible recurrence at an early stage, thus be
controlled with further salvage measures [35].
Trilateral Rb: The optimal therapy for patients with trilateral Rb is
not known, however treatment have progressively resulted in
increased survival of patients in the last 20 years [35]. Before 1995 the
five-year survival rate of trilateral Rb was 6 per cent compared to 44
per cent. Current research suggests that successful treatment of
trilateral Rb includes screening at diagnosis and treating with high-
dose chemotherapy with stem cell transplant [35].
Psycho-Oncology
Increasingly, early diagnosis is possible because of early detection
[36]. As such, the focus of care has now expanded to survivorship, and
in particularly, the field of psycho-oncology [37-40]. Psycho-oncology
is the psychological, social and behavioural factors, and the response of
patients and their families, at all stages of the disease [41,42]. It is
aimed at improving the quality of survival of the patient and their
family [43] and is often split into two subfields, paediatric and adult
psycho-oncology. Psycho-oncology is a multi-disciplinary approach
involving medical staff, psychiatrists, psychologists,
neuropsychologists, social workers, schools and counsellors [44].
Although there are reports of a small percentage of cancer survivors
experiencing psychological distress, it remains under-diagnosed and
often undertreated in the oncology setting [45]. Unfamiliarity of the
symptoms, misinterpretation, patients not subscribing to the
preconception of their experience, and shortcomings of the measuring
instruments used are common reasons [46,47].
Childhood cancer survivorship
When a person faces the diagnosis of cancer, they are not only
subjected to changes in their physical health but also changes to self-
perception and social relationships [45]. Although the majority of
childhood cancer survivors adjust well to life after cancer, a subgroup
of survivors experience problems as a consequence of the disease or
due to the treatment [48]. This can result in adverse life-long
psychological distress [43].
Distress is common in cancer patients and can manifest in the
clinical syndrome of anxiety and depression or as worries, fears and
stress [40-42]. This may be due to a loss of independence, reduced
energy levels, lack of enjoyment in previously enjoyed activities,
communication and emotional difficulties, discrepancies between
anticipated and achieved goals, and maintenance of unhelpful coping
mechanisms [37].
Psychosocial, clinical or maladaptive coping strategies can arise at
varying times often related to developmental changes. Along with the
normal developmental changes such as development of own identity,
decision making and intimate relationships, childhood cancer
survivors are also at risk of chronic health problems which affect
academic achievement, impair or decrease social relationships and
lead to low self-esteem [39]. As the childhood cancer survivor reaches
adolescence, they may start to experience cancer-related concerns
including the experience and consequence of physical, psychological
and social changes. Often these concerns are expressed indirectly to
their care team and more often when family members are not present.
As young cancer survivors become settled into adulthood, educational
concerns around their personal cancer history and late effects may
become more important [38].
A childhood cancer survivor moving through adolescence to a
young adult can experience vulnerability. Follow-up consultations
based upon psycho-oncology models, and programs that are sensitive
to the developmental trajectory from childhood to adulthood are of
upmost importance.
The cancer survivor’s family
Childhood cancer not only affects the child but also their family.
Paediatric psycho-oncology care includes late effects for the child’s
family [43]. The majority of parents of children with cancer will act as
their caregiver placing them at an increased risk of developing anxiety
and depression due to changes in family dynamics, socioeconomic
status and their own coping strategies [46].
Parents are most likely to worry on a daily basis about recurrence of
the disease, the child’s school performance, lack of friends, physical
side-effects and job opportunities. This often results in the parent
experiencing uncertainty, loss and loneliness [49] and with siblings
experiencing loneliness and a change in family dynamics. Effective
communication with their parents and attending support groups has
been found to reduce some of these feelings [50].
The impact of childhood cancer on cancer survivors, their parents
and siblings does not seem to decrease over time. The change in
parents’ and siblings’ perspective of life can influence the child’s mood
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and coping [51]. Thus, if the child picks up on the negative emotional
wellbeing of their parents and siblings, then they are likely to
experience psychological distress that can impede their own emotional
and physical wellbeing. These findings support the notion that
psychosocial care needs to incorporate the families’ strengths and
limitations in order to provide the best level of support for those who
need it [41].
Measures and interventions
Whilst the Quality of Life and the Health-Related Quality of Life
measurements take into consideration the social, cognitive, emotional
and physical functioning of the patient, assessing only the negative
aspects of health, fails to distinguish between related concepts such as
wellbeing and health status and variations in the sources of
information, e.g. doctors overestimating physical symptoms; parents
focusing on long-term effects; and the child focusing on immediate
effects [51].
Without a fully functional assessment measure, the practical
application of clinical interventions that addresses specific concerns of
patients falls short, mostly due to a lack of information and guidance
[41]. Patient’s whose psychological needs are not met are less likely to
tolerate treatment and late effects such as secondary cancers [52].
The Psycho-Oncology Consultation Model developed by Deshields
and Nanna [41] includes goals of care and specific interventions that
clinicians can use. The model advocates care of the “whole” patient
which includes addressing the mental health needs of the cancer
patient, facilitation of effective communication between patient and
care providers, developing healthy coping strategies, enhancing self-
efficacy, addressing information needs, and reducing distress.
Due to the intensity of treatment and time availability and
resources, interventions should be delivered on a least intrusive and
most effective basis often starting at the first session [41]. Eliciting the
patient’s story, their current resources for coping and support
mechanisms through normalising and validation are essential to
provide the patient and their families with practical, educational and
social support by making efficient and effective referrals. Specific
treatment options for patients experiencing clinical symptoms such as
depression and anxiety include Cognitive Behaviour Therapy and
relaxation, both of which have a positive long-term effect on quality of
life [53].
The parents
Due to the early age of Rb diagnosis, parents become the primary
decisions makers and therefore, seek an active advocacy role in their
child’s health care needs [54]. Confronted with information that is
difficult to digest and poorly communicated, such as treatment
options, risks and outcomes, parents can become easily overwhelmed
and misunderstand what is being asked of them. This can sometimes
result in delayed treatment decisions that may put the child at a
disadvantage [54]. General and disease-specific information that is
presented at a level each parent is able to understand, improves
parental adjustment, increases their understanding of risk, and
potentially improves outcomes and compliance with treatment [55].
Ek and colleagues [56] found that parents’ emotional reactions are
particularly strong after the diagnosis and first treatment of their child
for Rb, with feelings of shock and unreality. This is soon replaced with
feelings of emptiness, tiredness and gratefulness that their child is
alive. Having somebody to confide in can ease the emotional burden
experienced.
Various quality of life measures have been conducted investigating
parents’ own perceived quality of life and those of their children. On
reporting their own quality of life, parents scored lower than the
general population indicating that having a child who is cured from Rb
still impacts their own emotional wellbeing [57]. This could be due to
psychosocial and medical worries and fears such as their child
developing secondary cancers, their education attainment and social
relationships. Investigating the coping experience of parents of a child
with Rb Hamama-Raz et al. [58] found that parents’ strengths as
individuals and partners, and their ability to separate thoughts and
emotions, made them more equipped to cope leading to improved
quality of life.
When asked to rate their child’s quality of life, parents’ perceived
their general and emotional health as poor and reported more
emotional and behavioural problems, despite the quality of life of their
child, being no different from the general population [57]. Although
parents report more behavioural problems in their child than the
actual child, van Dijk et al. [59] found that both parents and survivors
reported the survivor internalising their emotional and behavioural
problems by becoming depressed, anxious and withdrawn. Parents
may overrate the behavioural problems of the child as a result of their
own coping strategies in dealing with the uncertainties and their own
adjustment to their circumstances [59].
Parents of children who had bilateral Rb and those who received
chemotherapy reported their child had low participation levels in
community related activities, possibly due to the relationship between
participation and quality of life. Sheppard et al [60] found that
mothers reported their child had a good quality of life when being
interviewed. However, when the same questions were asked using
standardised measures, mothers rated their child’s quality of life as
poor. This raises questions about methodology in assessing quality of
life and is worthy of further investigation.
The survivor
There is little follow up data on Rb survivors which has tended to
focus on coping strategies and quality of life [60]. The use of task and
avoidant orientated rather than emotion orientated mechanisms in
stressful situations may account for this [61]. Enhancing certain
qualities that make them better at coping with adversity puts the
survivors at the same level of functioning as the general population
[61]. The discrepancy between the survivor’s quality of life and that as
perceived by their parents appears to be a reflection of the parents’
coping mechanism rather than the child’s actual functioning.
Rb survivors who use emotion orientated coping strategies are likely
to experience behavioural problems such as self-blame, anger and
isolation resulting in maladjustment. Behavioural problems are also
associated with level of social support, life events and acceptance of the
disease [61]. Monitoring and support of these individuals is therefore
required. With minimal literature on how to support survivors of Rb,
the guidelines from the Institute of Medicine and the Psycho-
Oncology Consultation Model are advised.
Ross et al. [62] found that the majority of Rb survivors exhibit good
health, physical development and normal mental and motor ability.
However, 39 per cent of Rb survivors needed an intervention to
improve their visuo-motor development and children diagnosed with
bilateral Rb needed more support than those with unilateral Rb.
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Treatment intensity may be the cause of this but so may be self-care,
relationships and mobility [63].
Health-related quality of life of survivors has been found to be the
same as with the general population. However, they perceive their
quality of life at school as lower compared to their healthy peers [57].
Willard et al [64] examined the developmental functioning of infants
and young people with Rb through the first five years of their life.
Their findings point to a low level range of functioning that led to a
significant decline over time. This is in contrast to previous findings of
survivors demonstrating above average intellectual functioning
compared with the general population [65] and so is controversial.
Continual assessment of cognitive functioning in Rb survivors as
they age is required to capture a full picture of intellectual functioning.
Educational environment, time away from school, relationship and
support from peers and teachers are crucial factors [66], as indeed is
stress [67], and biomarkers of stress [68-71]. Parents, caregivers and
healthcare workers often underestimate young children’s
understanding about their illness and their resilience. Assumptions are
too often made on what a good quality of life is for the survivor and
their families. Giving a voice to the survivors and their families on
their own wellbeing is essential in order to create a fully patient-
centred and individualised model of care that addresses lifestyle,
psychological and social aspects of cancer, especially in young
individuals who are just beginning to express themselves in growing
up.
Summary
Chemo-reduction with or without focal therapy is the most
commonly employed conservative treatment for Rb [11]. Although an
effective treatment, tumour and associated vitreous and sub-retinal
seeds can recur within the first 3 years [35].
Thus, chemo-reduction is most successful for tumours without sub-
retinal and vitreous seeding: group A-B on the International
Classification for Intraocular Rb and groups I-IV on the Reese-
Ellsworth Classification for Intraocular Rb. Enucleation stands alone
as the treatment of choice for patients with tumours that fill more than
75 per cent of the eye.
High-dose chemotherapy with stem cell transplant is the treatment
of choice following enucleation for patients with extra-ocular Rb stage
I to IV and for trilateral Rb.
The relatively small numbers of Rb cases coupled with non-
comparable staging systems, for example the Reese-Ellsworth had
resulted in little research into this prolific disease [31]. However, over
the last twelve years collaboration between national and international
centres has resulted in an increase in the evidence base of Rb
management.
Current research is directed towards genotype-phenotype
relationship, local drug delivery methods, minimising side effects of
treatments, developing better animal models and exploring biological
treatment such as growth factors [72]. Supportive treatment for the
patient and their families are currently more focused upon the physical
health rather than the psychological impact of the disorder.
Psych-oncology models are helpful in addressing the coping
mechanisms, providing support, and providing a voice for young
survivors of Rb.
Acknowledgement
Author 2 is funded is by the Vice Chancellor’s Open Scholarship for
Postgraduate Research at Bournemouth University.
References
1. Childhood Eye Cancer Trust (2014) About retinoblastoma. Accessed:
13.02.2015. http://www.chect.org.uk/cms/index.php/about-rb.
2. Huang D, Zhang Y, Zhang W, Wang Y, Zhang P, et al. (2013) Study on
clinical therapeutic effect including symptoms, eye preservation rate, and
follow-up of 684 children with retinoblastoma. Eur J Ophthalmol 23:
532-538.
3. Ray A, Gombos DS, Vats TS (2012) Retinoblastoma: an overview. Indian
J Pediatr 79: 916-921.
4. Shields CL (2008) Forget-me-nots in the care of children with
retinoblastoma. Semin Ophthalmol 23: 324-334.
5. Macmillian (2013) Rb in children. Accessed: 13.02.2015. http://
www.macmillan.org.uk/Cancerinformation/ Cancertypes/
Childrenscancers/Typesofchildrenscancers/Rb.aspx -
DynamicJumpMenuManager_6_Anchor_1.
6. Balmer A, Zografos L, Munier F (2006) Diagnosis and current
management of retinoblastoma. Oncogene 25: 5341-5349.
7. Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE, Hurwitz R
(2007) Retinoblastoma: review of current management. Oncologist 12:
1237-1246.
8. Meel R, Radhakrishnan V, Bakhshi S (2012) Current therapy and recent
advances in the management of retinoblastoma. Indian J Med Paediatr
Oncol 33: 80-88.
9. Canty CA (2009) Retinoblastoma: an overview for advanced practice
nurses. J Am Acad Nurse Pract 21: 149-155.
10. Children with Cancer (2014) Retinoblastoma, UK. Accessed: 13.02.2015. 
http://www.childrenwithcancer.org.uk/Rb
11. Moll AC1, Imhof SM, Cruysberg JR, Schouten-van Meeteren AY, Boers
M, et al. (2003) Incidence of retinoblastoma in children born after in-
vitro fertilisation. Lancet 361: 309-310.
12. Ramirez-Ortiz MA, Ponce-Castaneda MV, Cabrera-Munoz ML, Medina-
Sanson A, Liu X, et al., (2014) Diagnostic delay and sociodemographic
predictors of stage at diagnosis and mortality in unilateral and bilateral
retinoblastoma. Cancer Epidemiology, Biomarkers & Prevention
23:784-792.
13. Bio-Quick news – life science news from around the world. Accessed:
13.02.2015. http://www.bioquicknews.com/node/1975.
14. Genetics Home Reference (2009) RB1. Accessed 13.02.2015. http://
ghr.nlm.nih.gov/gene/RB1
15. Knudson AG Jr, Hethcote HW, Brown BW (1975) Mutation and
childhood cancer: a probabilistic model for the incidence of
retinoblastoma. Proc Natl Acad Sci U S A 72: 5116-5120.
16. MacCarthy A, Bayne AM, Draper GJ, Eatock EM, Kroll ME, et al. (2009)
Non-ocular tumours following retinoblastoma in Great Britain 1951 to
2004. Br J Ophthalmol 93: 1159-1162.
17. Fontela J, Massana A, Pelegrín A, Aranda A, Burés M, et al., (2005)
Retinoblastoma. La Medicina Hoy LXVIII1564:33-34.
18. American Cancer Society (2014) Retinoblastoma: Early detection,
diagnosis and staging topics. Accessed: 13.02.2015. http://
www.cancer.org/cancer/Rb/detailedguide/Rb-staging
19. Chen Z, Moran K, Richards-Yutz J, Toorens E, Gerhart D, et al., (2014)
Enhanced sensitivity for detection of low-level germline mosaic RB1
mutations in sporadic retinoblastoma cases using deep semiconductor
sequencing. Human Genome Variation Society 35:384-391.
20. Limn YS, Juraida E, Alagaratnam J, Menon BS (2011) Trilateral
retinoblastoma. Med J Malaysia 66: 156-157.
21. Keating P, Dahmen JC, King AJ (2013) Context-specific reweighting of
auditory spatial cues following altered experience during development.
Curr Biol 23: 1291-1299.
Citation: Thompson SBN,Chinnery H, Noroozi S, Dyer B, Barratt K (2015) Retinoblastoma: Identifying the Diagnostic Signs for Early Treatment.
Int J Neurorehabilitation 2: 1000160. doi:10.4172/2376-0281.10001360
Page 9 of 11
Int J Neurorehabilitation
ISSN:2376-0281 Open Access Volume 2 • Issue 2 • 160
22. Carlyle T (1837) The French revolution: a history. The Modern Library,
New York.
23. Canadian Cancer Society (2014) Retinoblastoma: prognosis and survival.
Accessed: 13.02.2015. https://www.cancer.ca/en/cancer-information/
cancer-type/Rb/prognosis-and-survival/?region=on
24. Goel GK, Jain D, Goel D, Juneja P (2012) Rehabilitation after surgical
treatment for retinoblastoma: ocular prosthesis for a 6-month-old child. J
Prosthodont 21: 408-412.
25. National Institute of Clinical Excellence (NICE) (2005) Children's
tumours - suspected: retinoblastoma. Accessed 13.02.2015. http://
cks.nice.org.uk/childrens-tumours-suspected - !
scenariorecommendation:8
26. Kiss S, Leiderman YI, Mukai S (2008) Diagnosis, classification, and
treatment of retinoblastoma. Int Ophthalmol Clin 48: 135-147.
27. Shields CL, Schoenberg E, Kocher K, Shukla SY, Kaliki S, et al., (2013)
Lesions simulating retinobalstoma (pseudoretinoblastoma) in 604 cases:
results based on age at presentation. Ophthalmology 120:311-316.
28. Hernandez JC, Brady LW, Shields JA, Shields CL, DePotter P, et al.,
(1995) External beam radiation for retinobastoma: results, patterns of
failure, and a proposal for treatment guidelines. International Journal of
Radiation Oncology, Biology & Physics 35:125-132.
29. Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, et al. (2006) The
International Classification of Retinoblastoma predicts chemoreduction
success. Ophthalmology 113: 2276-2280.
30. Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, et al. (2004)
Chemoreduction for retinoblastoma: analysis of tumor control and risks
for recurrence in 457 tumors. Trans Am Ophthalmol Soc 102: 35-44.
31. Chawla B, Jain A, Azad R (2013) Conservative treatment modalities in
retinoblastoma. Indian J Ophthalmol 61: 479-485.
32. Yan J, Zhang H, Li Y (2013) Establishment of the relationship between
tumor size and range of histological involvement to evaluate the
rationality of current retinoblastoma management. PLoS One 8: e80484.
33. Eye Cancer Network (2014) Enucleation surgery: removal of the eye.
Acessed: 13.02.2015. http://www.eyecancer.com/conditions-and
treatments/treatments/3/ enucleation-surgery-removal-of-the-eye
34. Reppucci ML, Fulco EM, Shields CL (2012) Management of advanced
retinoblastoma with intraarterial chemotherapy. Ocular oncology case
reports in ocular oncology. Accessed: 13.02.2015.http://
fighteyecancer.com/wpcontent/uploads/2013/10/ managment-of-
advanced-Rb-with-intraarterial-chemotherapy-2012-retina-today-
reppucci-marina-copy-copy.pdf
35. de Jong MC, Kors WA, de Graaf P, Castelijns JA, Kivela T, et al. (2014)
Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet
Oncol 15: 1157-1167.
36. Dukes C, Thompson SBN, Heathcote D (2013) Treating PTSD in cancer
patients. Oncology 4:1-15.
37. von Blanckenburg P, Seifart U, Conrad N, Exner C, Rief W, et al. (2014)
Quality of life in cancer rehabilitation: the role of life goal adjustment.
Psychooncology 23: 1149-1156.
38. McClellan W, Klemp JR, Krebill H, Ryan R, Nelson EL, et al. (2013)
Understanding the functional late effects and informational needs of
adult survivors of childhood cancer. Oncol Nurs Forum 40: 254-262.
39. Patenaude AF, Kupst MJ (2005) Psychosocial functioning in pediatric
cancer. J Pediatr Psychol 30: 9-27.
40. Thompson SBN, Eccleston L, Hickish T (2011) Post-traumatic stress
disorder in cancer survivors: recognising and acknowledging the
symptoms. Oncology 2:1-16.
41. Deshields T, Nanna S (2010) Providing care for the "whole patient" in the
cancer setting: the Psycho-Oncology Consultation Model of patient care.
Clinical Psychology in Medical Settings 17:249-257.
42. Abbey G, Thompson SB, Hickish T, Heathcote D (2015) A meta-analysis
of prevalence rates and moderating factors for cancer-related post-
traumatic stress disorder. Psychooncology 24: 371-381.
43. Van Dongen-Melman JE (2000) Developing psychosocial aftercare for
children surviving cancer and their families. Acta Oncol 39: 23-31.
44. Askins MA, Moore BD 3rd (2008) Psychosocial support of the pediatric
cancer patient: lessons learned over the past 50 years. Curr Oncol Rep 10:
469-476.
45. de Vries M, Friedrich S (2014) Psycho-oncological interventions and
psychotherapy in the oncology setting. In: Psycho-Oncology, Goerling U
(Ed.), Springer-Verlag Publishing, pp:121-135, New York.
46. Patenaude AF, Last B (2001) Cancer and children: where are we coming
from? Where are we going? Psychooncology 10: 281-283.
47. Sinclair HA, Hamill C (2007) Does vicarious traumatisation affect
oncology nurses? A literature review. Eur J Oncol Nurs 11: 348-356.
48. Mellblom A, Finset A, Korsvold L, Loge J, Ruud E, Lie H (2014)
Emotional concerns in follow-up consultations between paediatric
oncologists and adolescent survivors: a video-based observational study.
Psycho-Oncology 23:1365-1372.
49. Williams L, McCarthy M, Eyles D, Drew S (2013) Parenting a child with
cancer: perceptions of adolescents and parents of adolescents and
younger children following completion of childhood cancer treatment.
Journal of Family Studies 19:80-89.
50. Houtzager B, Grootenhuis M, Last B (1999) Adjustment of siblings to
childhood cancer: a literature review. Support Care Cancer 75:302-320.
51. Vance Y, Morse R, Jenney M, Eiser C (2001) Issues in measuring quality
of life in childhood cancer: Measures, proxies, and parental mental
health. Journal of Child Psychology and Psychiatry 42;5:661-667.
52. Oeffinger KC, Wallace WH (2006) Barriers to follow-up care of survivors
in the United States and the United Kingdom. Pediatr Blood Cancer 46:
135-142.
53. Osborn RL, Demoncada AC, Feuerstein M (2006) Psychosocial
interventions for depression, anxiety, and quality of life in cancer
survivors: meta-analyses. Int J Psychiatry Med 36: 13-34.
54. Panton RL, Downie R, Truong T, Mackeen L, Kabene S, et al. (2009) A
visual approach to providing prognostic information to parents of
children with retinoblastoma. Psychooncology 18: 300-304.
55. Beaudin JS, Intille SS, Morris ME (2006) To track or not to track: user
reactions to concepts in longitudinal health monitoring. J Med Internet
Res 8: e29.
56. Ek U, Seregard S, Jacobson L, Oskar K, Af Trampe E, et al. (2002) A
prospective study of children treated for retinoblastoma: cognitive and
visual outcomes in relation to treatment. Acta Ophthalmol Scand 80:
294-299.
57. Weintraub N, Rot I, Shoshani N, Pe'er J, Weintraub M (2011)
Participation in daily activities and quality of life in survivors of
retinoblastoma. Pediatr Blood Cancer 56: 590-594.
58. Hamama-Raz Y, Rot I, Buchbinder E (2012) The coping experience of
parents of a child with retinoblastoma-malignant eye cancer. J Psychosoc
Oncol 30: 21-40.
59. van Dijk J, Oostrom KJ, Imhof SM, Moll AC, Schouten-van Meeteren
AY, et al. (2009) Behavioural functioning of retinoblastoma survivors.
Psychooncology 18: 87-95.
60. Sheppard L, Eiser C, Kingston J (2005) Mothers' perceptions of children's
quality of life following early diagnosis and treatment for retinoblastoma
(Rb). Child Care Health Dev 31: 137-142.
61. van Dijk J, Grootenhuis MA, Imhof SM, Cohen-Kettenis PT, Moll AC, et
al. (2009) Coping strategies of retinoblastoma survivors in relation to
behavioural problems. Psychooncology 18: 1281-1289.
62. Ross G, Lipper EG, Abramson D, Preiser L (2001) The development of
young children with retinoblastoma. Arch Pediatr Adolesc Med 155:
80-83.
63. van Dijk J, Oostrom KJ, Huisman J, Moll AC, Cohen-Kettenis PT, et al.
(2010) Restrictions in daily life after retinoblastoma from the perspective
of the survivors. Pediatr Blood Cancer 54: 110-115.
64. Willard VW, Qaddoumi I, Chen S, Zhang H, Brennan R, et al. (2014)
Developmental and adaptive functioning in children with
retinoblastoma: a longitudinal investigation. J Clin Oncol 32: 2788-2793.
65. Williams M (1968) Superior intelligence of children blinded from
retinoblastoma. Arch Dis Child 43: 204-210.
Citation: Thompson SBN,Chinnery H, Noroozi S, Dyer B, Barratt K (2015) Retinoblastoma: Identifying the Diagnostic Signs for Early Treatment.
Int J Neurorehabilitation 2: 1000160. doi:10.4172/2376-0281.10001360
Page 10 of 11
Int J Neurorehabilitation
ISSN:2376-0281 Open Access Volume 2 • Issue 2 • 160
66. Bassell A (2001) Children surviving cancer: psychological adjustment,
quality of life, and school experiences. Exceptional Children 67:345-359.
67. Rodriguez EM, Dunn MJ, Zuckerman T, Vannatta K, Gerhardt CA, et al.
(2012) Cancer-related sources of stress for children with cancer and their
parents. J Pediatr Psychol 37: 185-197.
68. Thompson SBN, Frankham C, Bishop P (2014) The art of capturing a
yawn using the science of nerve impulses and cortisol levels in a
randomized controlled trial. Thompson Cortisol Hypothesis as a
potential predictor of neurological impairment. International Journal of
Arts & Sciences 7:529-543.
69. Thompson SBN, Rose K, Richer S (2014) Yawning with cortisol:
examining the neuroscience behind the Thompson Cortisol Hypothesis
for supporting rehabilitation of neurologically impaired individuals.
Journal of Neuroscience & Rehabilitation 1:1-11.
70. Thompson SB (2014) Yawning, fatigue, and cortisol: expanding the
Thompson Cortisol Hypothesis. Med Hypotheses 83: 494-496.
71. Thompson SBN (2014) This will make you yawn. New Scientist
224:3000/3001:38-39.
72. Rushlow D, Piovesan B, Zhang K, Prigoda-Lee NL, Marchong MN, et al.
(2009) Detection of mosaic RB1 mutations in families with
retinoblastoma. Hum Mutat 30: 842-851.
 
Citation: Thompson SBN,Chinnery H, Noroozi S, Dyer B, Barratt K (2015) Retinoblastoma: Identifying the Diagnostic Signs for Early Treatment.
Int J Neurorehabilitation 2: 1000160. doi:10.4172/2376-0281.10001360
Page 11 of 11
Int J Neurorehabilitation
ISSN:2376-0281 Open Access Volume 2 • Issue 2 • 160
